Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
aflibercept (zaltrap) (3 trials)
pegaptanib (macugen) (1 trial)
bevacizumab (avastin) (1 trial)
ranibizumab (lucentis) (2 trials)
stakel (1 trial)
kvd001 (1 trial)
Choroidal Neovascularization (Phase 2)
Edema (Phase 3)
Macular Degeneration (Phase 4)
Macular Edema (Phase 4)
Neovascularization, Pathologic (Phase 2)
Retinal Vein Occlusion (Phase 4)
Trials (7 total)
Trial APIs (6 total)